The Company operates in one reportable segment. Sales to customers outside the U.S. represented 18%, 17% and 14% of total revenue for the years ended December 31, 2017, 2016 and 2015, respectively. As of December 31, 2017 and 2016, balances due from foreign customers, in U.S. dollars, were $18.8 million and $6.8 million, respectively.

The Company had sales to individual customers in excess of 10% of total revenue, as follows:



	Year ended December 31,
	2017		2016		2015
Customer:
A	21	%	16	%	20	%
B	20	%	15	%	17	%
C	13	%	13	%	11	%
	54	%	44	%	48	%

As of December 31, 2017 and 2016, accounts receivable from individual customers with balances due in excess of 10% of total accounts receivable totaled $44.4 million and $13.9 million, respectively.

The following presents long-lived assets (excluding intangible assets) and total net revenue by geographic territory (in thousands):



	Long-lived assets as of December 31,				Total revenue for the years ended December 31,
	2017		2016		2017		2016		2015
Domestic	$	59,833	$	50,774	$	227,611	$	158,244	$	168,809
Foreign	1,752		84		50,132		33,359		27,320
Total	$	61,585	$	50,858	$	277,743	$	191,603	$	196,129

Consolidated net revenues by product category are as follows (in thousands):



	Year ended December 31,
	2017		2016		2015
Rapid Immunoassay	$	165,099	$	121,416	$	130,348
Cardiac Immunoassay	47,030		—		—
Specialized Diagnostic Solutions	51,978		60,681		60,358
Molecular Diagnostic Solutions	13,636		9,506		5,423
Total revenues	$	277,743	$	191,603	$	196,129